You can’t trust a cost claim on its own. For any health plan finance team looking at a pilot program, the economic projection is worthless without a hard look at the patient engagement record that backs it up. This isn’t academic. It’s the only way to judge if a healthcare AI solution is actually viable, particularly when its entire model depends on people using it day in and day out.
Cost and Engagement Aren’t Separate Things
Everyone gets excited about the cost savings promised by new health tech. But if a program promises to slash costs and then nobody actually uses it, those savings will never appear. It’s simple math. Cost effectiveness and patient engagement are locked together, where engagement is the one true signal that tells you if the financial model works in the real world. A clinically perfect, theoretically cheap intervention is just a theory if patients don’t stick with it. This is especially true for digital health tools and AI platforms where the whole point is that user adherence creates the therapeutic (and economic) benefit.
What the Field Data Shows
Just look at the track records of companies like Virta Health, Omada Health, and Pear Therapeutics. Their whole business model lives or dies based on whether patients actually use their programs. It’s no surprise that both Virta and Omada show up in our data for cost and engagement. Their financial story is all about how well their tech and clinical models get people to stick around. Then you have the FDA’s Center for Devices and Radiological Health (CDRH) adding another layer. The SaMD regulatory path gives you a baseline for safety, but it’s just a baseline. So the FDA has cleared over 200 cardiac AI devices (far fewer than radiology’s 1,230), but that clearance doesn’t mean the product will sell or that patients will use it. The lesson is clear: you have to read cost and engagement claims together, always, even with an FDA stamp of approval.
Cleared Doesn’t Mean Commercial Success
Our data is littered with FDA-cleared products that went bust. It’s a brutal reminder that regulatory approval doesn’t guarantee a thing in the market. Take Pear Therapeutics. They had cleared products, but their story ended in bankruptcy and an asset sale in 2023 because they couldn’t translate that regulatory win into a business that could scale patient engagement. At the end of the day, the entire economic equation rests on people actually using the product. On the other hand, you have a platform like Hello Heart with a mountain of clinical proof: over six peer-reviewed studies with more than 28,000 people, showing a 21 mmHg drop in systolic blood pressure for high-risk members who stick with it for three years. One study even found $1,709 in savings per user and 47% fewer inpatient days, working across different demographics Hello Heart clinical validation studies. That kind of evidence sets a high standard for what’s possible. But even with that incredible backing, a health plan will only see those benefits if their specific members actually open the app and use it.
The One Question Finance Teams Should Ask
So when a vendor pitches an AI solution, what’s the first question a finance team should ask? It’s this: “What is your recorded engagement rate, and show me exactly how that number connects to your cost savings projection.” This is the main filter for everything else they say. Forget the glossy ROI projections for a minute and dig into the real metrics, adherence rates, how long people actually use it, completion rates for different parts of the program. That data gives you a much better picture of potential return than a spreadsheet ever will. And think about the model itself. There’s a reason human-in-the-loop systems often work better. One big systematic review of 65 randomized controlled trials found that AI helping a clinician beat an unassisted clinician 71% of the time, while AI alone only beat the clinician in 25% of cases Lancet Digital Health AI RCT review. For finance people, this means the way the engagement is designed, is it pure AI, or is there a human coach or nurse involved?, has a huge impact on whether you’ll see a clinical or financial return. The best AI health companies are the ones selling a proven engagement model, with published, real-world data showing the economics actually work when real people use their product.
Frequently Asked Questions
How does patient engagement impact the economic projections of a healthcare AI pilot program?
A program promising cost reductions will fail to deliver if it does not achieve meaningful patient engagement. Cost effectiveness and patient engagement are inextricably linked, with engagement signaling whether the economic model holds in real-world delivery. Without consistent patient participation, even clinically sound interventions remain unrealized potential.
Does FDA clearance guarantee commercial success or patient uptake for a cardiac AI device?
No, FDA clearance signifies a level of clinical validation but does not inherently guarantee commercial success or patient uptake. The article highlights instances where FDA-cleared material did not survive commercially, underscoring that regulatory approval is not a guarantee of market adoption or sustained patient use.
What key metrics should finance teams prioritize when evaluating a healthcare AI solution for a pilot program?
Finance teams should prioritize the recorded engagement rate for the solution and how it directly informs projected cost savings. A detailed understanding of patient engagement metrics, such as adherence rates, duration of use, and completion rates for program modules, provides a more accurate picture of potential return on investment than cost projections alone.
What is the significance of human-in-the-loop models for healthcare AI solutions?
Evidence suggests that AI-assisted clinicians often outperform unassisted clinicians, indicating that engagement with the AI solution, when augmented by human oversight or interaction, can significantly enhance outcomes. This implies that the design of the engagement model, whether autonomous or incorporating human support, critically influences both clinical effectiveness and the realization of cost benefits.
